Kautilya

Centre to Withdraw 100 Companies of Paramilitary Forces from Jammu

The Centre on Wednesday decided to withdraw 100 companies of security forces from the Union Territory of Jammu and Kashmir. The decision was taken after a security review by the ministry of home affairs (MHA). The companies of paramilitary personnel to be withdrawn include 40 companies of CRPF and 20 each of the BSF, CISF and SSB from the Kashmir Valley, officials said.

An Indian was the First to Scientifically Document A Tornado’s Path

Babu ChunderSikur Chatterjee, an Indian scientist employed with the Surveyor General of India during the British colonial era, was likely the first person to scientifically document a tornado’s path in 1865, claims a study from the Indian Institute of Tropical Meteorology (IITM), Pune. By carefully searching and analysing papers about tornados, Saumyendu De and Dr A K Sahai, scientists at IITM Pune, concluded that Chatterjee’s paper is the earliest record of a tornado’s dynamics in the history of meteorology.

India’s First Indigenous Aircraft Carrier ‘Ready’ for Basin Trials in September

Major endeavour to manufacture Aircraft Carrier is heading for an important phase as the first Indigenous Aircraft Carrier (IAC), INS Vikrant, is set to begin testing in waters (Basin Test) with its systems and equipment fitted. Basin trials are conducted for proving of the propulsion (move), transmission (electricity) and shafting systems which can be tested only out of waters.

Cipla and Stempeutics Collaborate for , First ‘Made in India’ Cell Therapy to Treat Critical Limb Ischemia

Cipla Limited referred to as “Cipla” today announced that its partner Stempeutics Research Pvt. Ltd has received regulatory approval by the Drug Controller General of India (DCGI) for the launch of Stempeucel® in India. The product is indicated for the treatment of CLI due to Buerger’s Disease and Atherosclerotic Peripheral Arterial Disease. It is the first allogeneic cell therapy product to be approved for commercial use in India and the first stem cell product to be approved globally for CLI treatment.